The European HIV Vaccine Alliance (EHVA) program has as major goal to develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines.
The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials in the field of HIV vaccines.
Project aims: The Specific Objectives of the MVP are to build up: 1) Discovery Platform. 2) Immune Profiling Platform 3) Data Management/Integration/Down-Selection Platform 4) Clinical Trials Platform.
Duration: 60 months from January 2016
Project leader: Institut national de la santé et de la recherche médicale (INSERM)
Main partners: Involves 39 institutions including universities, research institutes, SMEs, patient organisations and larger industries.
EATG participation: Involved in WP 8: Therapeutic Vaccine Trials; WP 10: Dissemination and Exploitation. EATG is community partner in this project ensuring community feedback to the scientific developments within the project.
Main funding source: EC Horizon 2020